Literature DB >> 9734366

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.

L Gu1, Y Okada, S K Clinton, C Gerard, G K Sukhova, P Libby, B J Rollins.   

Abstract

Recruitment of blood monocytes into the arterial subendothelium is one of the earliest steps in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1), a CC chemokine, is one likely signal involved in this process. To test MCP-1's role in atherogenesis, low density lipoprotein (LDL) receptor-deficient mice were made genetically deficient for MCP-1 and fed a high cholesterol diet. Despite having the same amount of total and fractionated serum cholesterol as LDL receptor-deficient mice with wild-type MCP-1 alleles, LDL receptor/MCP-1-deficient mice had 83% less lipid deposition throughout their aortas. Consistent with MCP-1 's monocyte chemoattractant properties, compound-deficient mice also had fewer macrophages in their aortic walls. Thus, MCP-1 plays a unique and crucial role in the initiation of atherosclerosis and may provide a new therapeutic target in this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734366     DOI: 10.1016/s1097-2765(00)80139-2

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  390 in total

Review 1.  Gene targeting of chemokines and their receptors.

Authors:  D M Slattery; N Gerard; C Gerard
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Genetics of atherosclerosis: the search for genes acting at the level of the vessel wall.

Authors:  V Villa-Colinayo; W Shi; J Araujo; A J Lusis
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

Review 3.  Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets.

Authors:  P Aukrust; J K Damås; L Gullestad; S S Frøland
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

4.  Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 5.  NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?

Authors:  T Collins; M I Cybulsky
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 6.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 7.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction.

Authors:  Matthias Nahrendorf; Mikael J Pittet; Filip K Swirski
Journal:  Circulation       Date:  2010-06-08       Impact factor: 29.690

8.  Monocyte chemoattractant protein 1 regulates pulmonary host defense via neutrophil recruitment during Escherichia coli infection.

Authors:  Gayathriy Balamayooran; Sanjay Batra; Theivanthiran Balamayooran; Shanshan Cai; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

Review 9.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

10.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.